GLP-1 drugs for PCOS: what the evidence actually supports

What did @bianca.hwb actually say?

She's doing her one-milligram Ozempic dose and openly admits she's scared of it. Why? Because tirzepatide (Mounjaro) gave her bad enough side effects that she developed what she calls PTSD around injection day. Since switching to semaglutide, she's been inconsistent with her shots specifically because of that fear, not because she forgot or didn't care.

This is a remarkably honest admission. She's not claiming anything dramatic about the drugs. She's describing medication anxiety driven by a real prior bad experience, and she says she knows she needs to stay consistent despite the fear. That's the whole video. No miracle claims, no dosing advice, just a person being candid about something a lot of GLP-1 users quietly experience but rarely say out loud.

Does the science back this up?

Yes, the general experience she's describing is well-documented. Side effect profiles between tirzepatide and semaglutide differ in meaningful ways, and treatment discontinuation due to gastrointestinal side effects is a real and studied problem in this drug class.

A 2023 meta-analysis by Tan et al. in Diabetes, Obesity and Metabolism found that GI adverse events, including nausea, vomiting, and diarrhea, are the leading reason patients discontinue GLP-1 receptor agonists. Tirzepatide, which acts on both GIP and GLP-1 receptors, has a distinct side effect profile compared to semaglutide. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) reported nausea in roughly 30% of patients on the highest tirzepatide dose. That's not a small number.

The phenomenon of anticipatory anxiety after a bad medical experience, what she loosely calls PTSD, is also recognized in clinical literature. Injection-related fear and avoidance behavior have been documented in insulin-dependent diabetes populations and are increasingly flagged in GLP-1 adherence research.

What did they get wrong (or right)?

She got the subjective experience right. She got the emotional honesty right. What's worth flagging is what she didn't say, not what she said incorrectly.

She's treating inconsistent dosing as a personal failing driven by fear, but the clinical reality is that irregular GLP-1 dosing can actually worsen side effects. Skipping doses and restarting disrupts the steady-state plasma concentration these drugs rely on, which means the next dose can hit harder. If anything, the fear of side effects that causes inconsistency can become a self-fulfilling cycle.

She also uses the term "tirzepatide" correctly when clarifying the generic name for Mounjaro, which is a level of accuracy you genuinely don't see enough on GLP-1 TikTok. No exaggerated claims, no promised outcomes. She's just doing her shot and talking about being scared. That's accurate to her experience and she isn't misleading anyone.

What should you actually know?

If you've had a rough experience on one GLP-1 medication, your side effect experience on another may differ, but that doesn't mean you're safe to skip doses on the new one. Consistency matters pharmacologically, not just for weight outcomes.

GI side effects from GLP-1 drugs are strongly tied to titration speed. Clinical guidelines recommend slow dose escalation precisely to reduce the severity of nausea and vomiting. If someone had a terrible experience that may partly reflect too-fast titration or no dietary adjustment during ramp-up, that context matters when switching drugs.

Injection anxiety is also underaddressed in telehealth. A 2021 study by Gonzalez et al. in Diabetes Care found that psychological barriers to injectable medication use, including fear and avoidance, significantly affected adherence even when patients understood the medical need. This is a clinical issue, not a willpower issue, and providers should be screening for it.

If you're on a GLP-1 and dreading your shot day because of past side effects, that's worth bringing up with whoever is prescribing it. Dose timing, food choices around injection day, and titration pace are all adjustable variables.